| Identification | Back Directory | [Name]
H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT | [CAS]
23815-89-6 | [Synonyms]
RPPGF
1-5-Bradykinin
BRADYKININ (1-5)
ARG-PRO-PRO-GLY-PHE
1-5-Bradykinin (9CI)
Arg-Pro-Pro-Gly-Phe-OH
BRADYKININ FRAGMENT 1-5
39: PN: WO0112656 SEQID
H-Arg-Pro-Pro-Gly-Phe-OH
ARG-PRO-PRO-GLY-PHE ACETATE
H-ARG-PRO-PRO-GLY-PHE-OH TFA
L-Arg-L-Pro-L-Pro-Gly-L-Phe-OH
Bradykinin Fragment 1-5, ≥97% (HPLC)
H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT
N5-(Diaminomethylene)-L-ornithyl-L-prolyl-L-prolylglycyl-L-phenylalanine
Bradykinin (1-5) trifluoroacetate salt H-Arg-Pro-Pro-Gly-Phe-OH trifluoroacetate salt | [Molecular Formula]
C27H40N8O6 | [MDL Number]
MFCD03788122 | [MOL File]
23815-89-6.mol | [Molecular Weight]
572.66 |
| Chemical Properties | Back Directory | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
3.50±0.10(Predicted) | [color ]
White to off-white | [Sequence]
Arg-Pro-Pro-Gly-Phe | [InChIKey]
USSUMSBPLJWFSZ-UHFFFAOYSA-N | [SMILES]
NC(CCCNC(N)=N)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NCC(=O)NC(Cc3ccccc3)C(O)=O |
| Hazard Information | Back Directory | [Uses]
Biologically active fragment of bradykinin | [Biochem/physiol Actions]
The bradykinin (BK) fragment (1-5) (RPPGF) is among the most stable of naturally occurring metabolites. It may be used as a marker for BK production in vivo. It is known that an intact Arg residue in the C-terminus is required for biological activities. BK 1-5 is the minimal peptide that inhibited α-thrombin-induced platelet aggregation and secretion and calcium mobilization. It also prevented α-thrombin from cleaving the thrombin receptor peptide, NATLDPRSFLLR, between arginine and serine. Such antithrombin activities of BK 1-5 may contribute to the cardioprotective nature of kinins. | [in vivo]
Bradykinin is a short-lived vasoactive peptide, with a reported half-life in vivo of 17 s, that is rapidly metabolized in the circulation to Bradykinin (1-5). Bradykinin (1-5), the product of two sequential cleavages of Bradykinin by ACE at the Pro7-Phe8 and Phe5-Ser6bonds, has been identified as the major stable metabolite of Bradykinin in vivo in human subjects, with a terminal half-life of minutes. Both Bradykinin and Bradykinin (1-5) inhibit α- and γ-thrombin-induced platelet aggregation (P<0.01 versus baseline). Bradykinin (1-5) inhibits γ-thrombin-induced platelet aggregation 50% at a calculated dose of 183±3 pmol/min. Neither Bradykinin nor Bradykinin (1-5) affects thrombin receptor-activating peptide-induced platelet aggregation, consistent with the hypothesis that Bradykinin and Bradykinin 1-5 inhibit thrombin-induced platelet aggregation by preventing cleavage of the thrombin receptor and liberation of thrombin receptor-activating peptide. Bradykinin (1-5) significantly attenuates α-thrombin-induced platelet aggregation but not TRAP 1-6-induced platelet aggregation. Bradykinin (1-5) potently inhibits γ-thrombin (500 nM)-induced platelet aggregation with an ED50 of 183±2 pmol/min[1]. |
|
| Company Name: |
Sigma-Aldrich
|
| Telephone: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|